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The Epstein-Barr virus early antigen diffuse component (EA-D) is essential for Epstein-Barr virus DNA
polymerase activity, and its activity is suppressed during latent infection. We investigated the regulation of the
promoter (BMRFl) for this early gene by studying its responsiveness in vitro to two immediate-early viral
transactivators, BZLF1 (Z) and BRLF1 (R), focusing on the differences in response in lymphoid cells and
epithelial cells. In lymphoid cells, Z or R alone produced only small increases in EA-D promoter activity,
whereas both transactivators together produced a large stimulatory effect. In epithelial cells, the Z
transactivator alone produced maximal stimulation of the EA-D promoter; the effect of R and Z together was
no greater than that of Z alone. Deletional analysis and site-directed mutagenesis of the EA-D promoter
demonstrated that in epithelial cells the potential AP-1 binding site plays an essential role in Z responsiveness,
although sequences further upstream are also important. In lymphoid cells, only the upstream sequences are
required for transactivation by the Z/R combination, and the AP-1 site is dispensable. These data suggest that
EA-D (BMRF1) promoter regulation by Z and R is cell type specific and appears to involve different
mechanisms in each cell type.
Epstein-Barr virus (EBV) is a herpesvirus that infects
primarily B cells and epithelial cells (17, 28, 32). EBV
infection of B cells is predominantly latent, whereas
epithelial-cell infection is often productive (28), raising the
question of whether there are different mechanisms for
regulation of viral expression in lymphoid and epithelial
cells. Overexpression of the immediate-early (IE) EBV gene
product, BZLF1, in EBV-infected B cells is sufficient to
convert latent expression to productive infection (10, 13, 29,
33). The BZLF1 gene (Z) encodes a 34- to 38-kilodalton
nuclear protein (the Z protein) which has sequence similarity
to the DNA-binding site of the c-fos protein and binds to the
AP-1 binding site (7), although there is no potential leucine
zipper (36) in the Z protein. Exactly how the Z protein binds
to the AP-1 site, or whether binding of Z to AP-1 or closely
related sites is always required for transactivation of target
promoters, is still unknown. Although the Z protein appears
to play a key role in determining whether EBV infection is
latent or productive, the disruption of latency is likely to
involve other EBV transactivators.
Two other EBV IE gene products have been shown to
encode transactivator functions. The BMLF1 gene product
has been shown by several groups to transactivate a number
of homologous and heterologous promoters (4, 14, 16, 24, 37)
linked to chloramphenicol acetyltransferase (CAT). How-
ever, we have shown that the BMLF1 effect is reporter gene
dependent and does not result in significantly increased
levels of mRNA (14). The role of the BMLF1 gene in
induction of lytic viral infection remains unknown.
The BRLF1 gene also encodes an IE transactivator func-
tion (1, 3, 4, 11, 12). The BRLF1 gene product is a 94- to
98-kDa protein which localizes to the nucleus and cytoplasm
(5, 26). As shown by cDNA analysis, the BRLF1 protein (R)
is derived from a bicistronic mRNA which also encodes the
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Z protein (25), suggesting that the regulation of Z and R is
tightly linked. The R transactivator, in contrast to Z, cannot
disrupt viral latency when transfected and overexpressed in
cells (5).
Several EBV early promoters are transactivated by either
Z or R. The genes activated by Z include BMLF1, BMRF1,
the BZLF1 gene itself, and the divergent promoter (DR/DL)
(1-5, 12, 13, 23, 25, 31, 35). Z-responsive elements in these
promoters have been mapped within 100 base pairs (bp) of
the TATA box, and the response elements have included
AP-1 (or closely related) binding sites. The R transactivator
activates the DR promoter and the BMLF1 promoter (1-3, 5,
12). The R-responsive regions in both of these promoters
reside within upstream enhancer elements, and both of these
R-responsive elements contain the same 14-bp sequence
motif, CCGTGGAC/GAATGTC. Whether the R transacti-
vator binds to DNA is unknown at present.
In the work described in this paper, we have studied the
regulation of the EBV BMRF1 early promoter, EA-D. The
BMRF1 gene encodes the early antigen diffuse (EA-D)
protein, which is an essential component of the viral DNA
polymerase activity (22). EA-D activity is suppressed in
latent infection and reactivated during productive infection
(6). We show here that the EA-D promoter is differentially
regulated in lymphoid and epithelial cells. In epithelial cells,
the Z transactivator alone is sufficient to transactivate the
EA-D promoter. In contrast, in lymphoid cells, Z transacti-
vation of the EA-D promoter cells is inefficient unless the R
transactivator is also present. We demonstrate here that the
potential AP-1 binding site in the EA-D promoter is essential
for Z-induced transactivation in epithelial cells, but is not
required for the Z/R combined effect in lymphoid cells.
MATERIALS AND METHODS
Cell lines. The cell lines used include the EBV-negative
Burkitt's lymphoma B-cell line (Louckes), a T-cell line
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FIG. 1. Construction of pEA-CAT deletions. The parent
pEA-CAT construct contains the EBV BamHI-RsaI fragment (EBV
nucleotides 79537 to 79898) linked to CAT. A series of 5' deletion
mutants were constructed by cutting at the indicated restriction
endonuclease site, blunt ending with T4 polymerase or Klenow
enzymes, and religating. The TATA box and a potential AP-1
binding site are shown.
(Jurkat), a cervical epithelial-cell line (HeLa), and a laryn-
geal epithelial-cell line (HEp-2). All lymphoid cell lines were
maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum. HeLa and HEp-2 cells were maintained in
Dulbecco modified Eagle medium H supplemented with 10%
fetal calf serum.
DNA transfections. Plasmid DNA was purified through two
sequential cesium chloride gradients. DNA was transfected
into both lymphoid and epithelial cell lines by electropora-
tion (34). For each condition, 107 cells were shocked at 1,500
V with the Zapper electroporation unit (Medical Electronics
Shop, University of Wisconsin). Epithelial cells were har-
vested and suspended into RPMI 1640 medium for electro-
poration.
EBV-CAT plasmids. EBV-CAT plasmids were con-
structed by inserting EBV promoter sequences into the BglII
site of the plasmid vector pCAT3M (21). The plasmid
pCAT3M contains the bacterial CAT gene and the simian
virus 40 polyadenylation site but no eucaryotic promoter
element. The plasmid pM-CAT (12), as previously de-
scribed, contains the promoter of the EBV IE gene, BMLF1,
linked to the CAT gene. The pEA-CAT plasmid, which has
the promoter of the early EA-D gene, contains the 333-bp
EBV BamHI-RsaI fragment (nucleotides 79537 to 79898)
linked to the CAT gene. 5' deletion mutants of pEA-CAT
were made by cutting with the restriction enzymes illus-
trated in Fig. 1, blunt ending with T4 polymerase or the
Klenow enzymes, and religating to pCAT3M. The genome
map locations of each construct are shown in Fig. 1. The
plasmid pEA-BS-CAT was made (for use in in vitro
site-directed mutagenesis) by inserting the XbaI-BamHI
fragment from pEA-CAT (which contains the complete EA
promoter sequences, the CAT gene, and the polyadenylation
site) into the XbaI-BamHI site of the M13 Bluescript SK+
plasmid (Stratagene Inc.).
EBV transactivating plasmids. The pEBV-ZIE plasmid
(Fig. 2) contains the BamHI Z gene fragment (nucleotides
101741 to 103947) in the pGem2-based vector pHD1013 (15),
such that the BZLF1 gene is under the control of the strong














FIG. 2. Construction of the EBV transactivator plasmids. The
pEBV-ZIE transactivator plasmid was made by placing the BamHI
Z fragment into the BamHI site of pHD1013. This places the BZLF1
gene under control of the strong human CMV IE promoter. The
pEBV-RZ transactivator construct contains the BgII J fragment
inserted into the BamHI site of pHD1013. pEBV-RZ places both the
R and Z transactivating proteins under the control of the CMV IE
promnoter. The pEBV-RIE plasmid contains a HindIII-HindIII frag-
ment from pEBV-RZ containing the BRLF1 gene linked to the CMV
IE promoter ligated into a pUC-18 vector.
plasmid contains both the BRLF1 (R) and BZLF1 (Z)
transactivators under the control of the CMV-IE promoter
(both gene products can be made from a bicistronic mRNA).
This plasmid has the 4,061-bp BglII-BglII fragment (EBV
nucleotides 101351 to 105412) inserted into the BamHI site of
the vector pHD1013. In the pEBV-RIE plasmid, a
Hindlll-HindlIl fragment from pEBV-RZ (which contains
the BRLF1 gene linked to the CMV-IE promoter) was
ligated into the pUC18 vector. The construction of these
EBV transactivator plasmids is illustrated in Fig. 2.
CAT assays. Cells were transfected with 10 ,ug of plasmid
DNA as described above. At 48 h after transfection, a cell
extract was prepared and incubated at 37°C with
[14C]chloramphenicol in the presence of acetyl coenzyme A
as described previously (9). The percent acetylation of
chloramphenicol was quantitated by thin-layer chromatogra-
phy followed by autoradiography and scintillation counting.
If results were not in the linear range (less than 70%
chloramphenicol acetylation), CAT assays were repeated
with less extract.
RNA analysis. To quantitate CAT mRNA, we prepared
cytoplasmic RNA 24 h after transfection as previously
described (8). A 20-bp oligonucleotide primer homologous to
the CAT gene in the region 15 to 34 bp downstream of the
ATG codon was synthesized and end labeled with
[Y-32P]ATP. Labeled oligonucleotide (105 cpm) was hybrid-
ized overnight with cytoplasmic RNA in a solution contain-
ing 80% formamide, 40 mM PIPES [piperazine-N,N'-bis
(2-ethanesulfonic acid)], 400 mM NaCl, and 1 mM EDTA.
Primer extension (18) was performed at 42°C for 90 min with
avian myeloblastosis virus reverse transcriptase (27). The
primer extension products were electrophoresed on a 6%
acrylamide-7 M urea gel.
In vitro site-directed mutagenesis. Mutants were made by
using the Bio-Rad Muta-Gene phagemid in vitro mutagenesis
kit, based on a method described by Kunkel et al. (19, 20).
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FIG. 3. Effect of the Z and R transactivators on the BMRF1
(EA-D) early promoter versus the BMLF1 IE promoter. A 5-,ug
portion of either the pM-CAT plasmid (12) (which contains the
primarily R-responsive BMLF1 promoter) or the pEA-CAT plasmid
(-331 to + 1), which contains the early EA-D promoter, was
cotransfected with 5 p.g of either pEBV-ZIE (which encodes Z),
pEBV-RIE (which encodes R), or both transactivators together.
CAT assays were performed as described previously (9). CAT assay
results are presented as fold induction over basal levels. In lymphoid
cells (Louckes and Jurkat), the combination of R and Z is required
for maximal stimulation of the EA-D promoter, whereas R alone is
sufficient for maximal stimulation of the BMLF1 construct. In
epithelial cells (HeLa and HEp-2), Z alone produces maximal'
transactivation of the EA-D promoter, whereas R alone is sufficient
for maximal stimulation of the BMLF1 promoter.
Mutants were made by using a synthetic oligonucleotide
complementary to the region to be altered except for a
limited internal mismatch. For screening possible mutants,
synthetic oligonucleotides were created such that in vitro
mutations would create a new PvuII restriction site which
allows each possible mutant to be analyzed by digestion with
restriction endonucleases. Following initial screening, po-
tential mutants were sequenced with the Sequenase 2.0
enzyme sequencing kit (United States Biochemical Corp.) to
identify the mutation.
RESULTS
The EA-D promoter is differentially regulated in lymphoid
and epithelial-cell types. We have previously reported that
the EA-D promoter can be stimulated in both EBV-positive
and EBV-negative cell lines by cotransfection with the Z
transactivator plasmid (13). In this study we examined the
effects of the Z and R transactivators alone and in combina-
tion on EA-D promoter activity in different cell types. Figure
3 illustrates representative CAT assays in which the
pEA-CAT plasmid was cotransfected into various cell types
with either the pEBV-ZIE plasmid (which encodes BZLF1)
or the pEBV-RIE plasmid (which encodes BRLF1), or both
transactivators together.
In either B or T lymphoid cell lines (Louckes and Jurkat),
the EA-CAT promoter activity was only slightly increased
on cotransfection with either Z or R. However, when
pEA-CAT was cotransfected with both transactivators to-
gether in lymphoid cells, a large stimulatory effect was
obtained. This synergistic effect of Z and R together was
observed with either the pEBV-ZIE and pEBV-RIE plas-
mids in combination or the pEBV-RZ plasmid alone, which
expresses the bicistronic Z/R mRNA. In contrast, the plas-
mid pM-CAT, which contains the promoter of the EBV
BMLF1 gene and has been previously shown to be primarily
R responsive (12), is transactivated equally well by either R
alone or the combination of Z and R in Jurkat cells.
In the epithelial-cell lines HeLa and HEp-2, the Z trans-
activator alone produced a large stimulatory effect on
pEA-CAT activity. As in lymphoid cells, the R transactiva-
tor alone produced only a small effect. When both transac-
tivators were cotransfected into epithelial cells, the effect of
Z and R together upon EA-CAT activity was no greater than
that of Z alone. The pM-CAT plasmid, as expected, was
efficiently transactivated by either R alone or the R and Z
combination in HeLa cells. These data suggest that the Z
transactivator alone is sufficient to activate EA-D promoter
activity maximally in epithelial cells. In contrast, both Z and
R are required for efficient EA-D promoter transactivation in
lymphoid cells.
RNA analysis. Previous studies have shown that both the
Z- and R-induced transactivation of reporter gene constructs
is associated with a similar increase in steady-state RNA
levels (12, 13). In this study we analyzed the effect of the Z/R
transactivator combination on the steady-state level of
pEA-CAT RNA in lymphoid cells. In the experiment shown
in Fig. 4, 5 ,ug of the pEA-CAT construct was cotransfected
into Jurkat cells with 5 ,ug of either pHD1013 (lane B) or the
pEBV-RZ transactivator construct (lane C). Lane A con-
tains untransfected Jurkat RNA. Cytoplasmic RNA was
harvested 24 h after transfection and hybridized to a
y-32P-labeled primer homologous to the CAT gene sequence
15 to 34 bp downstream of the ATG codon, and primer
extension was performed as described in Materials and
Methods. Primer extension analysis clearly demonstrated an
increase in the steady-state level of pEA-CAT mRNA after
cotransfection with the Z/R transactivators. The mRNA
start site, which mapped to EBV sequence 79897, was not
altered in the presence of the two transactivators.
Localization of the Z- and R-responsive regions in the EA-D
promoter. To define the Z- and R-responsive region(s) of the
EA-D promoter, we created a series of 5' deletion mutants of
the pEA-CAT plasmid. These deletions are illustrated in Fig.
1. The parent pEA-CAT plasmid contains EBV nucleotides
79537 to 79898 (-331 to +1) relative to the RNA start site.
Four deletion plasmids were constructed (Fig. 1) which
delete progressively larger fragments of the upstream 5'
promoter sequences. The smallest construct, pEA-AT
(-62 to +29) contains only 62 bp upstream of the cap site. A
potential AP-1 binding site is located between -57 and -64
relative to the start site.
The effects of the Z, R, and Z/R transactivating proteins
on these pEA-CAT 5' deletions are summarized in Tables 1
and 2. In lymphoid cells (Table 1), the data indicate that
maximum transactivation of the parent pEA-CAT is
achieved only when both Z and R are present. The effect of
the Z transactivator alone could be significantly increased by
deleting the sequences from -331 to -265, although even
with this construct the effect of Z and R together was greater
than that of Z alone (85.3-fold transactivation versus
18.8-fold). A progressive loss of response to the Z transac-
tivator alone, or the Z-plus-R combination, occurred as 5'
Jurkot,..H. , " rZ
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TABLE 1. Effect of EBV-IE transactivators on pEA-CAT deletion plasmids in the Jurkat cell line
Plasmid Constitutive Fold increase in CAT activitybactivity" pEBV-ZIE pEBV-RIE pEBV-RZ
pEA(-331/+1)-CAT 1.3 (0.7-2.3) 3.7 (2.1-6.4) 3.1 (2.6-3.7) 33.7 (22.8-61.0)
pEA(-265/+1)-CAT 0.7 (0.6-1.0) 18.8 (4.0-31.2) 4.0 (2.2-5.3) 85.3 (50.5-119.5)
pEA(-214/+29)-CAT 0.9 (0.6-1.1) 4.2 (1.9-8.2) 2.5 (1.9-3.7) 23.3 (20.4-27.8)
pEA(-79/+1)-CAT 2.0 (1.3-2.4) 1.6 (0.5-2.4) 3.4 (1.2-4.5) 4.9 (4.4-5.8)
pEA(-62/+29)-CAT 4.7 (3.0-7.6) 1.5 (0.7-2.8) 1.6 (0.6-2.4) 1.7 (0.4-2.7)
a The numbers shown represent the average percent acetylation from four experiments. Ranges are given in parentheses.
b The numbers shown represent the average fold increase in CAT activity when each CAT plasmid was cotransfected with either pEBV-ZIE, pEBV-RIE, or
pEBV-RZ with respect to the activity with the pHD1013 vector. Ranges (in parentheses) are those from three experiments for pEBV-RIE and four experiments
for pEBV-ZIE and pEBV-RZ.
sequences between -265 and -62 were deleted, although
the region located between -265 and -214 appeared to play
the greatest role in the total transactivation. Neither the
intact pEA-CAT plasmid nor any of the 5' deletion mutations
were significantly transactivated with the R-gene product
alone in the Jurkat cell line.
In HeLa cells, maximum stimulation of the parent,
pEA-CAT, occurred with the Z transactivation alone (Fig.
3). Likewise, the effect of Z and R together on each mutant
was no greater than that of Z alone (data not shown). As in
lymphoid cells, a significant portion of the Z effect in HeLa
cells was lost when the sequences between -265 and -214
were deleted (Table 2). In contrast to the situation in
lymphoid cells, total Z response actually was increased in




FIG. 4. Primer extension analysis of pEA-CAT RNA. The
pEA-CAT plasmid was cotransfected into Jurkat cells with 5 ,ug of
either the pHD1013 vector (lane B) or the Z/R transactivating
plasmid, pEBV-RZ (lane C). RNA (50 ,ug) from untransfected Jurkat
cells (lane A) or pEA-CAT transfected cells was hybridized over-
night with a y-32P-labeled oligonucleotide primer homologous to
CAT gene sequences 15 to 34 bp downstream of the ATG codon.
Primer extension (18) was performed with reverse transcriptase at
42°C for 90 min (27). The mRNA start site mapped at EBV sequence
79897 and was not altered in the presence of the two transactivators.
Cotransfection with the R-plus-Z transactivator demonstrated an
increase in the steady-state level of EA-CAT mRNA (lane C), as
indicated by the arrow.
were deleted. In epithelial cells, the 17-bp region between
-79 and -62 (which contains a portion of the potential AP-1
binding site) also contributed to Z responsiveness, since the
pEA construct (-79 to +1) was 13-fold more responsive to Z
than the pEA construct (-62 to +29). The effect of R alone
in HeLa cells was too small to be accurately mapped.
Role of the AP-1 consensus site in Z and R transactivation of
the EA-D promoter. To better define the role of the AP-1
consensus site in Z- and Z/R-induced transactivation of the
EA-D promoter in different cell types, we constructed a
series of site-directed mutants of the EA-CAT construct by
using in vitro mutagenesis. To facilitate these studies, we
transferred the EA-D promoter sequences and CAT gene
from the pEA-CAT construct into a Bluescript M13 SK+
phagemid vector to create the construct pEA-BS-CAT.
Using the method of Kunkel et al. (19, 20), the 6 bp defining
the AP-1 binding site in pEA-BS-CAT was specifically
altered as shown in Table 3, leaving the rest of the promoter
unchanged. In addition, since analysis of the 5' deletion
mutants suggested that sequences further upstream from the
potential AP-1 site may also contribute to Z/R transactiva-
tion, three other site-directed mutants were constructed
which each remove potential AP-1-like binding sites lying
between -197 and -240. One additional mutant, which
alters a sequence (-185 to -198) containing a 10-of-14-bp
similarity to the shared R-response sequence region of the
DR and BMLF1 enhancers (1-3, 12) was also constructed.
The effects of the Z, R, and Z/R transactivators on these
site-directed mutants are shown in Tables 4 and 5.
The AP-1 site-directed mutation in pEAAAP1-CAT de-
creased Z-induced transactivation in HeLa cells by more
than 20-fold, confirming that the AP-1 consensus site plays a
major role in EA-D regulation in epithelial cells. However, in
lymphoid cells (Table 5), the AP-1 mutation produced little
TABLE 2. Effect of the BZLF1 transactivator on pEA-CAT
deletion plasmids in the HeLa cell line
Constitutive Fold increase in CATPlasmid activitya activityb
pEA(-331/+1)-CAT 0.7 (0.7-0.7) 65.0 (33.0-96.5)
pEA(-265/+1)-CAT 0.5 (0.4-0.6) 111.9 (94.5-129.2)
pEA(-214/+29)-CAT 0.7 (0.5-0.9) 2.5 (1.0-4.0)
pEA(-79/+1)-CAT 0.5 (0.4-0.6) 13.0 (12.0-14.9)
pEA(-62/+29)-CAT 0.5 (0.4-0.5) 1.1 (0.6-1.5)
a The numbers shown represent the percent acetylation produced by each
construct and are derived from two experiments. Ranges are given in
parentheses.
b The numbers shown represent the average fold increase in CAT activity
when each CAT plasmid was cotransfected with pEBV-ZIE with respect to
the activity with the pHD1013 vector. Ranges (in parentheses) are results of
two experiments.
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TABLE 3. Construction of in vitro site-directed
mutations in pEA-CAT
Plasmid Altered sequences relative Mutationsto mRNA start site
pEAA&AP1-CAT -57 to -63 TGACTCA- TCAGCTG
pEAAZA1-CAT -240 to -246 TGGCTCGb -TCAGCTG
pEAAZB2-CAT -230 to -236 AACTGCTb -* ACAGCTG
pEAAZA3-CAT -197 to -203 TCACCCAb -CAGCTGA
pEAAZB4-CAT -190 to -1% ACCAATGC --CAGCTGG
a The mutation AAP1 alters the perfect consensus AP-1 binding site located
between -57 and -63.
b Mutations AZA1, AZB2, and /ZB3 each alter sequences containing a
4-of-8-bp similarity to the consensus AP-1 site.
c The mutation AZB4 alters a sequence which shares a 10-of-14-bp similar-
ity with the previously described shared R-response regions in the EBV DR
and BMLF1 enhancers (2, 3, 12).
effect on the ability of Z and R together to transactivate the
EA-D promoter, suggesting that the ability of R to interact
synergistically with Z in lymphoid cells is not mediated by
increased Z binding to the consensus AP-1 site. None of the
other site-directed mutants significantly affected Z or
Z-plus-R transactivation in either cell type.
DISCUSSION
We have demonstrated in these studies that EA-D
(BMRF1) promoter regulation by the Z and R IE transacti-
vators is cell type specific and appears to involve different
mechanisms. In epithelial cells, the Z gene product effi-
ciently transactivates the promoter for the EA-D early gene,
whereas effective transactivation of the same promoter in
lymphoid cells requires the addition of the R transactivator.
These differences in transactivation efficiency correlate with
different mechanisms of transactivation. In epithelial cells,
the potential AP-1 binding site, in addition to promoter
sequences further upstream (-214 to -265), is required for Z
response. In lymphoid cells, the AP-1 site is dispensable for
Z-plus-R transactivation, although the upstream regulatory
sequences (-214 to -265) are essential. Therefore, the
ability of the R and Z transactivators to synergistically
activate the EA-D promoter in lymphoid cells appears to
involve a mechanism independent of Z binding to the AP-1
site.
The regulation of the EA-D promoter by Z and R is
distinct from that of other EBV promoters previously stud-
ied. We have previously shown that another EBV promoter,
BMLF1, responds to the R transactivator in either
TABLE 4. Effect of the BZLF1 transactivator on pEA-CAT site-
directed mutants in different cell types
Fold increase in CAT activitya in:
Plasmid
Jurkat cells HeLa cells
pPEA-BS-CAT 2.3 (1.4-3.2) 156.9 (60.6-326.0)
pEAAAP1-CAT 0.4 (0.3-0.5) 7.0 (5.3-7.6)
pEAAZA1-CAT 2.8 (0.9-4.6) 71.5 (47.8-95.4)
pEAAZB2-CAT 3.0 (2.0-4.0) 68.1 (36.9-117.5)
pEAAZA3-CAT 2.0 (2.0-2.1) 46.3 (41.6-52.1)
pEAAZB4-CAT 1.8 (1.1-2.6) 71.4 (49.2-93.5)
a The numbers shown represent the average fold increase in CAT activity
when each CAT plasmid was cotransfected with the pEBV-ZIE plasmid with
respect to the activity with the pHD1013 vector. Ranges (in parentheses) are
those from two experiments with Jurkat cells and three experiments with
HeLa cells.
TABLE 5. Effect of the combined BRLF1/BZLF1 transactivators
on pEA-CAT site-directed mutants in Jurkat cells
Plasmid Fold increase in CATactivitya
pEA-BS-CAT .................................... 43.1 (30.8-52.0)
pEAAAP1-CAT .................................... 50.3 (36.8-74.8)
pEAAZA1-CAT .................................... 110.3 (52.5-213.6)
pEAAZB2-CAT ..................................... 76.9 (22.8-163.2)
pEAAZA3-CAT .................................... 99.3 (61.4-138.0)
pEAAZB4-CAT .................................... 91.1 (37.2-197.6)
a The numbers shown represent the average fold increase in CAT activity
when each CAT plasmid was cotransfected with the pEBV-RZ plasmid with
respect to the activity with the pHD1013 vector. Ranges are those from two
experiments.
EBV-positive or EBV-negative lymphoid and epithelial
cells, and mapped the R-response region in this promoter to
a 140-bp enhancer element (12). Several investigators have
reported that in addition to R, the BMLF1 promoter can be
activated (although to a much lesser extent) by the Z
transactivator, and they have mapped the Z-response region
to an AP-1 site (1, 12, 30, 35).
Our studies suggest that the regulation of the BMLF1 and
BMRF1 (EA-D) promoters by the Z and R transactivators is
clearly different. The BMLF1 promoter is primarily R re-
sponsive, and the effect of R and Z together is no greater
than that of R alone (at least when levels of R and Z are not
limiting) (12). Furthermore, no tissue specificity in the ef-
fects of R or Z on BMLF1 promoter activity has been
observed (1, 12). Unlike the case with BMRF1, in the
BMLF1 promoter the R-responsive and Z-responsive re-
gions of the promoter clearly map to separate regions.
Studies involving the EBV divergent promoter (BHLF1
and BHRF1) have shown that the R and Z transactivators
are both involved in the regulation of this complex element.
The R-responsive region of this promoter element can be
clearly mapped to an enhancer region which contains a 14-bp
sequence similar to a sequence in the R-responsive enhancer
of the BMLF1 promoter (1-3, 12). The Z transactivator also
activates the BHLF1 promoter. Lieberman et al. (23) have
reported that regulation of the BHLF1 promoter by Z is
tissue specific, with the response region to Z being located in
sequences between -7 and -155 in Vero cells but localized
within sequences further upstream in EBV-positive lym-
phoid cells. However, it is possible that the Z effect ob-
served in EBV-positive cells was actually mediated by the R
transactivator and did not represent true tissue-specific
differences in Z response elements.
Although the DR enhancer region can be activated by R
alone and not by Z alone, Cox et al. have recently reported
that the combination of R and Z activates the DR enhancer
synergistically (5). This synergistic effect of the Z-plus-R
combination on the DR enhancer element is different from
the EA-D promoter effect described here in several ways.
The EA-D effect is tissue specific, with synergy occurring in
lymphoid cells but not epithelial cells. Although the EA-D
promoter appears to be primarily Z responsive in epithelial
cells, at least when the Z and R transactivators are tested
separately, the DR enhancer is primarily R responsive (2, 3,
5, 11). The DR enhancer has a clearly mapped R response
region which contains the 14-bp element CCGTGGACAAT
GTC (similar to the R response element in the BMLF1
promoter) and can transfer R responsiveness to heterologous
promoters. In contrast, the effect of R alone on the EA-D
promoter is minimal and does not map to a single region of
the promoter. Interestingly, the EA-D promoter does con-
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tain the sequence GCCTGACCAATGTC (from -185 to
-198), which has a 10-of-14-bp similarity to the 14-bp
element shared by the BMLF1 and DR enhancers. However,
the site-directed mutant EAAZB4-CAT, which mutates 6 bp
of the above sequence, continues to response to the Z-plus-R
combination. These data together suggest that the ability of
Z and R to act synergistically upon the EA-D promoter and
DR enhancer elements may occur through different mecha-
nisms.
It is not clear why the Z effect in epithelial cells is greater
with the pEA(-79/+1) construct than with the pEA(-214/
+29) construct. There may be two separate Z response
elements, one located between -214 and -264 and the other
located between -79 and -62. In this regard, we have found
that the BstEII-BstXI fragment (-79 to -264) is not suffi-
cient to transfer Z or Z/R responsiveness to the simian virus
40 early promoter in pAlOCAT (21) (E. Guthrie et al.,
unpublished results), suggesting that both the upstream and
downstream response elements may be required for maximal
transactivation. In epithelial cells, the ability of Z to trans-
activate the downstream response element may be inhibited
by sequences between -79 and -214. Interestingly, the
BHLF1 promoter sequences located between -155 and
-417 have been shown to exert a similar negative effect in
the ability of Z to transactivate this promoter in Vero cells
(23). Alternatively, the increased length of RNA leader
sequences in the -214/+29 and -62/+29 constructs may
inhibit the effect of Z. In either case, the importance of the
potential AP-1 binding site (located between -57 and -64)
for Z transactivation in epithelial cells was confirmed by site-
directed mutagenesis of the AP-1 site.
Exactly why the Z protein alone is sufficient to activate the
R promoter in epithelial cells, yet both the Z and R proteins
are required for maximum activation of lymphoid cells, is
still speculative. Perhaps there is a cellular factor expressed
in epithelial cells that replaces the function of the R protein.
If so, the mechanism of this hypothetical epithelial-cell
factor must be different from the mechanism of R, since the
AP-1 site is dispensable for the Z-plus-R interaction, but not
when Z alone is used in epithelial cells. There may be a
factor present in lymphoid cells, but lacking in epithelial
cells, that inhibits efficient binding of Z to the AP-1 site. In
this case the helper role ofR in lymphoid cells might involve
binding by Z to alternative upstream binding sites. Alterna-
tively, the effect of Z plus R in lymphoid cells might involve
direct EA-D binding by the R protein (with Z providing a
helper function in this case). A particularly interesting pos-
sibility is that Z and R might act synergistically through
protein-protein interactions. Distinguishing between these
possibilities will require further protein-DNA binding stud-
ies.
The findings presented here with Jurkat and HeLa cells do
not necessarily correlate with the regulation of EBV infec-
tion in vivo, since neither of these cell types can actually be
infected by EBV. It is possible that the differences observed
in EA-D promoter regulation in Jurkat cells and HeLa cells
are due to differences in the degree of cell differentiation
(since EBV tends to be more productive in more differenti-
ated cells) rather than to tissue-specific differences. Never-
theless, these findings may well have biological relevance in
EBV infection. The tendency for EBV infection to remain
latent in lymphoid cells may relate to the requirement in this
cell type for both transactivating proteins, Z and R, to be
expressed if transactivation of certain crucial promoters
such as EA-D and the DR enhancer element is to occur.
Likewise, the ability of Z alone to activate certain promoters
in epithelial cells, but not lymphoid cells, may contribute to
the relative permissiveness of this cell type for productive
viral infection. The requirement for R transactivation (in
addition to Z) for activation of certain promoters in lymphoid
cells suggests that R function is likely to be crucial in the
disruption of viral latency in lymphoid cells. However,
whether the R transactivating function is also required for
productive infection of epithelial cells remains to be deter-
mined.
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